Novartis Sees Avidity Drug Suffer Third Clinical-Trial Setback

Novartis announced that a treatment for a rare muscle-wasting disease failed a late-stage clinical trial. This marks the third clinical-trial setback for the company in one week. Novartis acquired Avidity Biosciences for $12 billion in 2024, with this medicine as a key asset in the acquisition.

Next story